Drug Search Results
More Filters [+]

MK-0773

Alternative Names: mk-0773, mk0773, mk 0773
Latest Update: 2023-09-25
Latest Update Note: News Article

Product Description

selective androgen receptor modulator (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20356837/)

Mechanisms of Action: SARM Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MK-0773

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Sarcopenia

Phase 1: Osteoporosis|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MK-0773-005

P2

Completed

Sarcopenia

2009-10-01

Sarcopenia Study

P2

Completed

Sarcopenia

2009-10-01

MK-0773-004

P1

Completed

Healthy Volunteers

2008-08-01

MK0773-003

P1

Completed

Osteoporosis

2006-04-01

Recent News Events